• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.

    2/13/25 1:44:26 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTPI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    PETROS PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    71678J209

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    71678J209


    1Names of Reporting Persons

    Ayrton Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    657,614.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    657,614.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    657,614.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    71678J209


    1Names of Reporting Persons

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    657,614.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    657,614.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    657,614.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    71678J209


    1Names of Reporting Persons

    Waqas Khatri
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    657,614.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    657,614.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    657,614.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PETROS PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    1185 Avenue of the Americas, 3rd Floor, New York, NY, 10036
    Item 2. 
    (a)Name of person filing:

    (i) Ayrton Capital LLC, (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and (iii) Waqas Khatri
    (b)Address or principal business office or, if none, residence:

    (i) Ayrton Capital LLC, 55 Post Rd West, 2nd Floor, Westport, CT 06880; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman P.O. Box 10250, Cayman Islands, and (iii) Waqas Khatri, 55 Post Rd West, 2nd Floor, Westport, CT 06880
    (c)Citizenship:

    (i) Ayrton Capital LLC: United States; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: Cayman Islands; and (iii) Waqas Khatri: United States
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    71678J209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Ayrton Capital LLC: 657,614; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 657,614; and (iii) Waqas Khatri: 657,614. Represents 657,614 shares of Common Stock issuable on the exercise of certain warrants (the "Warrants") and a conversion of convertible preferred stock (the "Preferred Shares"). The issuable shares of Common Stock related to the exercise of the Warrants and conversion of the Preferred Shares are both subject to a 9.99% beneficial ownership blocker. The shares reported herein represent Common Stock of Petros Pharmaceuticals, Inc. (the "Issuer") held by Alto Opportunity Master Fund, SPC- Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the "Reporting Persons").
    (b)Percent of class:

    The percentages reported below are based on (i) 10,014,872 shares of Common Stock of the Issuer that were outstanding as of November 12, 2024; and (ii) 657,614 shares of Common Stock issuable on the exercise of the Warrants and conversion of the Preferred Shares held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's Form 10-Q, filed on November 13, 2024. For the sake of clarity, the holdings of the Reporting Persons reported herein are as of December 31, 2024. (i) Ayrton Capital LLC: 6.2%; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 6.2%; and (iii) Waqas Khatri: 6.2%.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 657,614; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 657,614; and (iii) Waqas Khatri: 657,614

     (ii) Shared power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

     (iii) Sole power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 657,614; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 657,614; and (iii) Waqas Khatri: 657,614

     (iv) Shared power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ayrton Capital LLC
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Managing Member
    Date:02/13/2025
     
    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Director
    Date:02/13/2025
     
    Waqas Khatri
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri
    Date:02/13/2025
    Get the next $PTPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTPI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

    Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") by the United States Food and Drug Administration (the "FDA") for companies seeking Rx-to-OTC switch for pharmaceutical products. The Comp

    1/7/25 9:15:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

    Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. If this Software as a Service ("SaaS") and S

    12/17/24 9:00:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

    Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored >80% compreh

    9/11/24 9:15:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/6/26 5:30:07 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/2/26 5:00:51 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walker Wayne Remell was granted 500,000 shares, increasing direct ownership by 7,895% to 506,333 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/2/26 5:00:36 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    SEC Filings

    View All

    Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

    1/2/26 5:00:44 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Petros Pharmaceuticals Inc.

    25-NSE - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/20/25 2:51:13 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Petros Pharmaceuticals Inc.

    10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

    11/13/25 4:19:42 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/13/24 11:14:05 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Petros Pharmaceuticals Inc.

    SC 13G - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    2/14/24 3:38:38 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    Leadership Updates

    Live Leadership Updates

    View All

    Oblong Appoints Two New Directors to its Board

    Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

    5/30/23 8:00:00 AM ET
    $OBLG
    $PMCB
    $PTPI
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTPI
    Financials

    Live finance-specific insights

    View All

    The Urvan Group Issues Letter to AMMO Inc. Shareholders Regarding its Nomination of a Full Slate of Highly Qualified Candidates for Election to the Company's Board of Directors

    Delivers Overview of New Strategy for Leveraging AMMO's Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse    Highlights Long-Term Opportunity to Achieve $1 Billion in Annual Sales with Strong Cash Flows and Sustainable Margins, Resulting in Superior Value Creation for Shareholders Introduces Diverse Slate with Expertise in Corporate Governance, Ecommerce, Finance, M&A and Strategic Growth Across Relevant B2B and B2C Categories Steven Urvan (together with the other participants in his solicitation, the "Urvan Group" or "we"), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ:POWW) ("AMMO" or the "Co

    8/29/22 8:05:00 AM ET
    $AYRO
    $CLAR
    $DD
    Telecommunications Equipment
    Consumer Discretionary
    Recreational Games/Products/Toys
    Major Chemicals

    Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

    NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021. Recent Corporate Highlights: Entered collaboration with Dr. Drew Pinsky to bring awareness to men's health with a focus on driving awareness around erectile and other sexual dysfunctionsPartnered with leading global contract manufacturer to bring production of erectile dysfunction drug STENDRA® to the United StatesLaunched two self-selection studies for erectile dysfunction drug STENDRA®Announced positive over-the-counter (OTC) label compr

    4/1/22 7:00:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care